<DOC>
	<DOCNO>NCT01529424</DOCNO>
	<brief_summary>The purpose study evaluate dose/response pharmacodynamic effect ISIS ApoC-III Rx v . Placebo fast total apoC-III level .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Study ISIS ApoC-III Rx Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Severe hypertriglyceridemia HbA1c &gt; /=9.0 % , type 1 diabetes , history outpatient insulin use 2 week last year Body mass index ( BMI ) &gt; 40 kg/m2 History bariatric surgery currently weight loss drug Use oral contraceptive hormone replacement therapy statins unless stable 3 month prior dose Group 1 2 patient : Use systemic corticosteroid , fibrates , niacin , fish oil product contain omega3 fatty acid within 6 week dose . Group 3 patient : unable discontinue use systemic corticosteroid least 6 week prior dose ; use niacin , fish oil , product contain omega3 fatty acid unless stable well control dose least 30 day prior screen anticipate change study period . Group 4 patient : unable discontinue use systemic corticosteroid least 6 week prior dose ; use fibrates niacin , fish oil , product contain omega3 fatty acid unless stable well control dose least 30 day prior screen anticipate change study period . Use topical corticosteroid , anticoagulant , drug dietary supplement potential lipidaltering effect unless dose stable well control 30 day prior dose Any Screening laboratory value allow reference range Inability comply protocol study procedures Any significant illness condition may adversely affect subject participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypertriglyceridemia</keyword>
</DOC>